C2 PHARMA Expands API Portfolio with Global Regulatory Access Ahead of CPHI Barcelona
C2 PHARMA has expanded their API portfolio global access with new regulatory submissions and approvals, a pending new product launch and have signed on a new CMO, SMS Lifesciences.
Along with the C-DMF and CEP approvals, the filings continue to grow across C2 PHARMA’s API portfolio. The most recent submissions include:
o Brimonidine Tartrate
o CADIFA under submission
o Bitmatoprost
o Canadian-DMF under submission
o Pilocarpine Hydrochloride Micronized
o Korean K-DMF under submission
o Tropicamide
o China C-DMF under submission
The company will be exhibiting at CPHI Worldwide 2023 in Barcelona from the 24th to the 26th of October 2023 in Hall 4, Booth D49 with its affiliates, Logisitics4Pharma and ASM Research Chemicals. To schedule a meeting please reach out to [email protected].
Position your company at the heart of the global Pharma industry with a CPHI Online membership
-
Your products and solutions visible to thousands of visitors within the largest Pharma marketplace
-
Generate high-quality, engaged leads for your business, all year round
-
Promote your business as the industry’s thought-leader by hosting your reports, brochures and videos within your profile
-
Your company’s profile boosted at all participating CPHI events
-
An easy-to-use platform with a detailed dashboard showing your leads and performance